Myeloid-derived leukemias, such as acute promyelocytic leukemia and acute myeloid leukemia (AML), showed substantial gains in mCH, while lymphoid-derived diseases, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), revealed diverse mCH levels. This evidence concerns the gene PMCH and plasma cell myeloma.